#USA #Minneapolis #Bio-Techne #Spatial Biology #Protein Proximity

Bio-Techne Introduces Advanced Spatial Protein Proximity Detection Program

Bio-Techne Corporation (NASDAQ: TECH), a leading global provider of innovative life science tools, has announced an Early Access Program for its latest breakthrough in spatial biology: a sophisticated new assay designed for in situ detection of protein proximity. This groundbreaking assay, rooted in the Advanced Cell Diagnostics RNAscope™ technology, promises researchers the ability to visualize and understand functional interactions between proteins in intact tissues, thus offering a comprehensive spatial view of molecular signaling that underpins disease processes.

Advancing Protein Proximity Detection

The introduction of this next-generation assay marks a significant milestone in the realm of biological research. Traditional methods for analyzing molecular interactions within tissues either focus on different components separately or rely on bulk proximity assays that fail to deliver localization data. With Bio-Techne's innovative solution, researchers can experience a newly defined spatial resolution that highlights not just the existence of proteins but their interactions within the context of the tissue environment.

Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment, emphasized the significance of this advance, stating, "This new protein proximity assay opens the door to seeing functional interactions between proteins and not merely their presence in a tissue. It's a powerful step forward in understanding the dynamic interplay within tissues that drives both biology and disease."

Enhancing Research Capabilities

The potential applications of the spatial protein proximity assay are vast. By providing insights at a subcellular resolution, the assay can be particularly valuable for various research focus areas, including:

• - Immune Checkpoint Dynamics: Understanding the interaction and regulation of immune checkpoints can significantly influence cancer immunotherapy development.
• - Investigating Bispecific Antibodies: The ability to see interactions at a detailed level could help in designing more effective therapeutic antibodies.
• - Studying Protein Interactions at Synaptic Junctions: This application has critical implications for neurobiology and understanding neurological disorders.

Moreover, the assay was designed to be compatible with the RNAscope™ Multiomic LS workflow that operates on the BOND RX platform, which integrates seamlessly into existing lab workflows, allowing users to leverage this technology without major overhauls to their current practices.

Early Access Program

Bio-Techne is rolling out the Early Access Program to select academic institutions and researchers keen on incorporating this cutting-edge spatial protein proximity capability into their scientific practices. This initiative will enable these pioneers to explore the implications of the new assay before its widespread launch.

During the 2025 American Association for Cancer Research (AACR) annual meeting, Bio-Techne's scientific team will present proof-of-concept data and case studies, demonstrating the assay's capabilities and its potential to revolutionize the study of protein interactions within various biological contexts.

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) stands at the forefront of the life sciences sector, providing advanced tools and bioactive reagents crucial for research and clinical diagnostics. With a diverse product portfolio that supports scientific exploration into biological processes and the specific trajectories of diseases, Bio-Techne plays a vital role in drug discovery and reliable clinical testing.

With approximately 3,100 dedicated employees and net sales of around $1.2 billion in fiscal 2024, Bio-Techne continues to be a driving force in the biotechnology sector. To learn more about Bio-Techne and its expansive range of products, visit bio-techne.com or stay connected via social media platforms such as Facebook, LinkedIn, Twitter, and YouTube.